Biopharma Daily Stock Updates - 04/26/21

$XBI $139 +4%

Covid Updates

$GILD +1% Announces plans to expand Remdesivir in India. source


$MRNA +2% Entered into agreement with Sanofi to fill/finish servies for 200 million doses of COVID vaccine in September 2021. source


$IMNM -7% SARS-CoV-2 antibody cocktail neutralizes UK, South Africa, Brazil, and California variants in preclinical testing. source



Pipeline Updates

$SRRK +5% Issuance of US patent related to inhibitors of myostatin activation. source


$RETA +15% FDA acceptance of NDA for bardoxolone for CKD by Alport syndrome, PDUFA date 2/25/22. source


$KRYS +3% Modifications to the statistical analysis plan for the ph 3 study of B-Vec for DEB based on FDA feedback. source


$ALDX +8% Schedules conference call 4/27/21 to announce ph 3 INVIGORATE results. source


$ZSAN +8% PK study of Qtrypta to initiate in June 2021; required for the NDA resubmission. source


$VYGR +16% FDA clears IND for VY-HTT01 gene therapy candidate for Huntington's Disease. source


$PIRS +6% Entering into exclusive product license with Boston Pharmaceuticals for PRS-342. source


$QURE +8% FDA clinical hold removed on hemophilia B program. source


$IMAB +1% Olamkicept Phase 2 trial reports positive topline results. source


$NLTX +6% Clinical hold on NL-201 removed, Phase 1 trial will begin recruiting over next several months. source


$KPTI +4% EMA validated MAA to expand label in the EU for NEXPOVIO in combo with bortezomib and dexamethasone to treat MM. source


$AXSM +11% AXS-05 NDA accepted by FDA, PDUFA date set for August 22, 2021. source


$AZN +1% Selumetinib recommended for approval in the EU for neurofibromatosis type 1 and plexiform neurofibromas. source


$AZN +1% Tagrisso recommended for approval in the EU for lung cancer. source


$AZN +1% Nirsevimab Phase 3 MELODY trial met primary endpoint in RSV infections. source



Finance Updates

$ESPR +4% Receives final revenue-based funding of $50M from Oberland Capital. source


$ESPR +4% Expands partnership with Daiichi Sankyo, $30M up front and up to $175M in milestone payments. source

0 comments